“…NKFBIE, EGR2, and RPS15, although they have been studied less. [78][79] In a recent multicenter study conducted within ERIC, sequencing of TP53, NOTCH1, SF3B1, BIRC3 and MYD88 was performed in a large patient series (totaling 3,490 patients), revealing that TP53 and SF3B1 mutations, but not NOTCH1 mutations, remained as independent prognostic markers of shorter time to first treatment in multivariate analysis, even amongst patients expressing unmutated IGHV genes. 50 A few published clinical trials have also pointed to a prognostic and even predictive role of SF3B1 and NOTCH1 mutations in CLL, 28 where, in particular, the latter confers resistance to the anti-CD20 monoclonal antibodies rituximab 29 and ofatumumab, 80 however, this needs further exploration and validation.…”